| Del Cielo Home Care Services | |
| 601 E Main St Suite 300, Alice, Texas 78332 | |
| (361) 664-3484 | |
| Name | Del Cielo Home Care Services |
|---|---|
| Location | 601 E Main St Suite 300, Alice, Texas |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 459319 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 78022, 78071, 78102, 78330, 78332, 78333, 78335, 78336, 78339, 78340, 78341, 78342, 78343, 78349, 78351, 78352, 78353, 78355, 78357, 78358, 78359, 78361, 78362, 78363, 78368, 78370, 78372, 78373, 78374, 78375, 78377, 78379, 78380, 78381, 78382, 78383, 78384, 78385, 78387, 78389, 78390, 78391, 78393, 78401, 78402, 78404, 78405, 78406, 78407, 78408, 78409, 78410, 78411, 78412, 78413, 78414, 78415, 78416, 78417, 78418 |
| NPI Number | 1275526923 |
| Organization Name | GOLD HORSES, LLC |
| Doing Business As | DEL CIELO HOME CARE SERVICES |
| Address | 411 N King St, Alice, TX 78332 |
| Phone Number | 361-664-3484 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
| NPI Number | 1598762338 |
| Organization Name | LAREDO VISITING NURSES, INC. |
| Doing Business As | DEL CIELO HOME HEALTH & HOSPICE |
| Address | 411 N King St, Alice, TX 78332 |
| Phone Number | 361-664-3484 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
| Quality Rating: |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 94.8 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.7 | 99.6 |
| How often the home health team checked patients for depression | 99.8 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 66.5 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 72.9 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.9 | 96.4 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 66.3 | 79.6 |
| How often patients got better at getting in and out of bed | 65.5 | 81.1 |
| How often patients got better at bathing | 76.4 | 82.3 |
| How often patients’ breathing improved | 67.9 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 83.4 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 69.4 | 75 |
| How often home health patients had to be admitted to the hospital | 14.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 11 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 96.9 | 94 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
The patient survey data of Del Cielo Home Care Services is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 84 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 82 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 78 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 82 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 74 | 78 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Competitive young athletes are under increasing pressure to play only one sport year round, but such specialization could increase the risk of injuries, a Loyola University Health System study has found.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).
According to reports, the Obama administration continues to face stiff criticism from Catholic leaders over its contraception policies. Meanwhile, GOP presidential hopeful Mitt Romney has among his health policy advisers two people who are on the record in their opposition to the health he signed while governor of Massachusetts.
› Verified 1 days ago
Real Home Health Care Inc Location: 301 Lucero Street, Alice, Texas 78332 Ratings: NA Phone: (361) 668-3158 | |
Saldivar Home Health Inc Location: 618 Bluebonnet St, Alice, Texas 78332 Ratings: NA Phone: (361) 396-1204 | |
Del Cielo Home Care Services Location: 601 E Main St Suite 300, Alice, Texas 78332 Ratings: Phone: (361) 664-3484 | |
Carestat Provider Services Location: 171 Medical Center Blvd Unit D, Alice, Texas 78332 Ratings: Phone: (361) 241-4600 | |
Healthy Horizons Homecare Llc Location: 1006 E 6th St, Alice, Texas 78332 Ratings: Phone: (361) 396-1282 |